Apollo Hospitals show 17% growth in revenues; 27% growth in EBITDA

AHLL posts positive EBITDA alongside 22% top-line growth

Apollo Hospitals, EBITDA, AHLL, Prathap C Reddy, Prohealth, Oncology, New hospitals, Advantage Healthcare India, Non-communicable diseases, Critical care, Robust digital architecture, Apollo Proton Cancer Center, Interim Dividend

Apollo Hospitals has announced robust consolidated performance in Q3FY20.  The revenues grew 17% to Rs 25,295 million compared to Rs. 21,690 million in Q3FY19, aided by Healthcare services growth of 12% YoY and SAP growth of 22%. HC services grew 12% YoY was led by growth both in the mature hospitals and New Hospitals which grew 9% YoY and 16% respectively. EBITDA (Pre Ind AS 116) was at Rs. 3,195 million in Q3FY20 as against Rs 2,679 million in Q3FY19 a YoY growth of 19%. PAT grew by 9% to Rs 948 million in Q3FY20.

Dr Prathap C Reddy, Chairman, Apollo Hospitals said, “Our ‘Prohealth’ programme has been well received across all our centres, profoundly contributing to our objective of enhancing the focus on preventing Non-Communicable Diseases. Even as we widen the suite of preventive healthcare offerings, we are rapidly evolving our capabilities across key specialties such as Oncology, Neurosciences, Orthopaedics and Critical Care to meet the healthcare challenges of the Nation. The progress made by Apollo Proton Cancer Center is heartening, as it has elevated the country into a select league that is leveraging innovative technology to address the rapidly growing epidemic of cancer.

He added, “In addition to arming ourselves with newer offerings and treatment technologies, the resilience of our service model that offers comprehensive care across multiple centres and formats, is enabling us to maintain a focused trajectory of growth amidst a dynamic and fluid operating environment. We are steadily realising the synergies that we had anticipated would arise, from the broad range of healthcare services spanning high acuity care, day care, clinics and pharmacies, amplified by a robust digital architecture enabling us to continue on our journey towards touching a billion lives.”

At a glance:
New hospitals improve EBITDA margins from 6.6% to 10.1%
AHLL posts positive EBITDA alongside 22% top-line growth
The Board announces 65 % Interim Dividend of Rs 3.25 per Share
Apollo Hospitals wins six awards at the 3rd Edition of FICCI, Advantage Healthcare India
Q3 FY20 Standalone Revenues up 17% at Rs. 2,529 crore
EBITDA (Pre IND AS 116) up 19% at Rs. 319 crore
EBITDA (Post IND AS 116) up 41% at Rs. 377 crore
PAT up 9% at Rs. 95 crore
9MFY20 Standalone Revenues up 17% at Rs. 7,222 crore
EBITDA (Pre IND AS 116) at Rs. 902 crore, higher by 20% yoy
EBITDA (Post IND AS 116) at Rs. 1,067 crore, higher by 42% yoy
PAT grows 17% yoy to Rs. 265 crore
SAP business reported 22% growth in Revenues in Q3 FY20
EBITDA (Pre IND AS 116) grew by 37%, EBITDA margins at 6.09% in Q3 FY20
EBITDA (Post IND AS 116) grew by 108%, EBITDA margins at 9.3% in Q3 FY20
As on December 31, 2019, Apollo Hospitals had 7,470+ operating beds across the network (excluding AHLL & managed beds), out of which 14 were new hospitals with 1,990 operating beds. The new hospitals are expected to see increase in volumes and utilisation going forward.